3DD1
Crystal structure of glycogen phophorylase complexed with an anthranilimide based inhibitor GSK254
Summary for 3DD1
Entry DOI | 10.2210/pdb3dd1/pdb |
Related | 3DDS 3DDW |
Descriptor | Glycogen phosphorylase, liver form, N-acetyl-beta-D-glucopyranosylamine, PYRIDOXAL-5'-PHOSPHATE, ... (8 entities in total) |
Functional Keywords | glycogen phosphorylase hlgp, diabetes, allosteric enzyme, carbohydrate metabolism, disease mutation, glycogen metabolism, glycogen storage disease, glycosyltransferase, nucleotide-binding, phosphoprotein, pyridoxal phosphate, transferase |
Biological source | Homo sapiens |
Total number of polymer chains | 2 |
Total formula weight | 197988.36 |
Authors | Nolte, R.T. (deposition date: 2008-06-04, release date: 2009-04-21, Last modification date: 2023-08-30) |
Primary citation | Thomson, S.A.,Banker, P.,Bickett, D.M.,Boucheron, J.A.,Carter, H.L.,Clancy, D.C.,Cooper, J.P.,Dickerson, S.H.,Garrido, D.M.,Nolte, R.T.,Peat, A.J.,Sheckler, L.R.,Sparks, S.M.,Tavares, F.X.,Wang, L.,Wang, T.Y.,Weiel, J.E. Anthranilimide based glycogen phosphorylase inhibitors for the treatment of type 2 diabetes. Part 3: X-ray crystallographic characterization, core and urea optimization and in vivo efficacy. Bioorg.Med.Chem.Lett., 19:1177-1182, 2009 Cited by PubMed: 19138846DOI: 10.1016/j.bmcl.2008.12.085 PDB entries with the same primary citation |
Experimental method | X-RAY DIFFRACTION (2.57 Å) |
Structure validation
Download full validation report